Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Iloperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vanda Pharmaceuticals' Fanapt Approved by FDA for Acute Bipolar I Disorder Treatment
Details : Fanapt (iloperidone) is an atypical antipsychotic agent indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
Brand Name : Fanapt
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 02, 2024
Lead Product(s) : Iloperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Iloperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study
Details : Fanapt® (iloperidone tablets), a novel atypical antipsychotic, in the treatment of acute manic and mixed episodes associated with bipolar I disorder in adults. Fanapt® is currently approved by the FDA for the treatment of schizophrenia in adults.
Brand Name : Fanapt
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2022
Lead Product(s) : Iloperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?